BCGP common mistakes
BCGP · Understand the traps and how to avoid them.
Calculating a creatinine clearance for an older adult with the Cockcroft-Gault equation using an actual body weight in an obese or edematous patient, or using a serum creatinine that reflects low muscle mass without adjustment, then dosing a renally cleared drug on that number.
Candidates memorize one equation and apply it mechanically; they forget that Cockcroft-Gault was derived with actual weight, that obesity and edema inflate the estimate, and that sarcopenia in frail elders makes a 'normal' creatinine mask substantially reduced kidney function.
What to do instead
Before every renal dose decision, ask three questions: which weight (use ideal or adjusted body weight in obesity, not actual), does the creatinine reflect muscle mass (consider cystatin C or a higher presumed CrCl in low-muscle elders), and is the drug's label tied to a specific equation. Practice with a frail 82-year-old, 45 kg, SCr 0.9 case until the reflex is automatic.
Treating a hemoglobin A1c of 7.0-7.5% in a frail older adult with multiple comorbidities as a failure requiring treatment intensification, rather than as an appropriate individualized target.
Candidates carry the tighter targets drilled for younger adults and do not internalize that guidelines relax A1c goals (often 7.5-8.0% or higher) for limited life expectancy, hypoglycemia risk, and functional dependence, and that A1c itself is unreliable in anemia, CKD, and recent transfusion.
What to do instead
For every diabetes question, first classify the patient by health status (healthy, complex/intermediate, very complex/poor health) and set the target before evaluating the regimen. Flag hypoglycemia risk from sulfonylureas and insulin as the dominant harm, and prefer agents with low hypoglycemia risk when deintensifying is the correct answer.
Selecting a benzodiazepine, a first-generation antihistamine, a strongly anticholinergic bladder antimuscarinic, or a long-acting sulfonylurea for an older adult without flagging it as potentially inappropriate and proposing a safer alternative.
Candidates recognize drug names but do not automatically run candidates through Beers Criteria or the anticholinergic burden scale; they also miss that 'as needed' and short-term use still count, and that the indication may allow a safer class.
What to do instead
Build a mental screen of the highest-yield Beers categories (benzodiazepines and Z-drugs, anticholinergics, antihistamines, sulfonylureas, NSAIDs, antipsychotics in dementia, proton pump inhibitors beyond eight weeks) and rehearse a substitute for each: CBT-I or melatonin for insomnia, a beta-3 agonist for urgency, SSRIs for depression, metformin or a DPP-4 inhibitor for diabetes.
Answering a heart failure question by adding a drug or increasing a dose without checking whether the regimen already contains a negative inotrope or fluid-retaining agent (non-dihydropyridine calcium channel blocker, thiazolidinedione, NSAID, high-dose sodium-containing effervescent preparation) that should be removed first.
The reflex is to optimize guideline-directed therapy forward, but exam items often hinge on recognizing an exacerbating drug; candidates under-weight the 'stop this' option when it appears alongside plausible 'add this' options.
What to do instead
For any decompensation scenario, run a structured medication review before titrating: exacerbating drugs, adherence, sodium and fluid intake, and renal function. Practice framing the answer as 'which single change most improves this patient's trajectory' rather than 'what is the next guideline drug'.
Recommending a standard adult dose of a newly started medication without applying age-related changes in volume of distribution, hepatic first-pass metabolism, and renal elimination, and without planning a start-low-go-slow titration and a monitoring parameter.
Candidates learn pharmacokinetic principles as isolated facts and do not connect them to concrete starting doses; they also forget that increased body fat prolongs half-life of lipophilic drugs while reduced total body water raises the concentration of hydrophilic ones.
What to do instead
For each new drug, state the pharmacokinetic rationale in one sentence (for example, lipophilic drug with prolonged half-life in increased adiposity, so start at half the adult dose), then name the monitoring parameter and the reassessment interval. Rehearse with benzodiazepines, gabapentin, warfarin, and digoxin.
Missing a clinically significant drug-drug or drug-disease interaction because the candidate reviews only the medications listed for the chief complaint rather than the full list, and does not consider cumulative anticholinergic or sedative burden across prescribers.
Case stems are long and candidates anchor on the presenting problem; additive toxicity across therapeutic classes (for example, an overactive bladder agent plus a tricyclic plus an antihistamine) is not visible unless the whole list is scanned systematically.
What to do instead
Read the entire medication list before reading the question. Then run three passes: pairwise interactions, cumulative anticholinergic/sedative/bleeding burden, and drug-disease contraindications (for example, NSAID in CKD or heart failure, anticholinergic in benign prostatic hyperplasia or dementia).
Recommending abrupt discontinuation of a long-term medication (benzodiazepine, opioid, antidepressant, corticosteroid, beta-blocker, proton pump inhibitor, antipsychotic) as the deprescribing answer, without a taper schedule and withdrawal monitoring.
Candidates learn that the drug is inappropriate and jump to 'stop it', conflating 'should not have been started' with 'can be stopped abruptly'; they underestimate withdrawal seizures, rebound, adrenal insufficiency, and rebound acid hypersecretion.
What to do instead
Every deprescribing recommendation must include three elements: a taper plan with a timeframe, a withdrawal or rebound symptom to monitor, and a non-drug or substitute strategy. Practice writing tapers for benzodiazepines (slow, often months), corticosteroids (stress-dose coverage), and PPIs (step-down or on-demand).
Attributing a new cognitive or functional decline in an older adult to dementia or normal aging without first excluding delirium and its precipitants (infection, dehydration, new drug, pain, constipation, urinary retention, sensory impairment).
Dementia is a familiar label and the acute change is embedded in a long stem; candidates under-use the confusion assessment method features of acute onset, inattention, and fluctuating course, and under-screen for anticholinergic and sedative precipitants.
What to do instead
Any acute change in mental status is delirium until proven otherwise. Systematically list precipitants, review the medication list for new or dose-changed culprits, and only then consider a dementia workup. If the item offers both a delirium workup and a dementia diagnosis, the workup comes first.
Choosing an antibiotic or dose for an older adult with pneumonia or urinary tract infection without adjusting for renal function, site penetration, and the distinction between asymptomatic bacteriuria and true infection.
Candidates pattern-match the diagnosis to a first-line drug and skip the renal dose adjustment and the culture data; they also treat a positive urine culture in a confused but otherwise stable patient as infection rather than evaluating for other causes of delirium.
What to do instead
For every infection item, state the organism or empiric spectrum, the renal dosing adjustment, and the site-specific penetration before selecting. Explicitly ask whether the criteria for true urinary tract infection are met (dysuria, suprapubic pain, fever, or systemic signs) rather than treating a culture alone.
Managing a care transition by discharging with a reconciled list only, without addressing adherence aids, health literacy, caregiver involvement, follow-up timing, and which clinician owns monitoring of each high-risk drug.
Candidates treat medication reconciliation as a documentation task and forget the evidence-based transition bundle; they also miss that the highest-risk period is the first days to weeks after discharge, when duplicate and omitted drugs cause harm.
What to do instead
For any transition item, cover five elements: reconciled and simplified list, patient and caregiver education with teach-back, follow-up appointment scheduled within the appropriate window, explicit monitoring plan with responsible clinician, and flagging of high-risk drugs (anticoagulants, insulin, opioids, diuretics). If one option omits follow-up or monitoring, it is usually wrong.